Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Previous Article in Special Issue
Viruses 2011, 3(7), 1041-1058; doi:10.3390/v3071041
Article

C7a, a Biphosphinic Cyclopalladated Compound, Efficiently Controls the Development of a Patient-Derived Xenograft Model of Adult T Cell Leukemia/Lymphoma

1,†
, 2,†
, 1
, 1
, 3
, 3
, 5
, 1
, 4
, 1,‡
 and 6,‡,*
Received: 17 May 2011; in revised form: 17 June 2011 / Accepted: 17 June 2011 / Published: 5 July 2011
(This article belongs to the Special Issue Recent Developments in HTLV Research)
Download PDF [762 KB, uploaded 5 July 2011]
Abstract: Adult T-cell leukemia/lymphoma (ATLL) is a highly aggressive disease that occurs in individuals infected with the human T lymphotropic virus type 1 (HTLV-1). Patients with aggressive ATLL have a poor prognosis because the leukemic cells are resistant to conventional chemotherapy. We have investigated the therapeutic efficacy of a biphosphinic cyclopalladated complex {Pd2 [S(−)C2, N-dmpa]2 (μ-dppe)Cl2}, termed C7a, in a patient-derived xenograft model of ATLL, and investigated the mechanism of C7a action in HTLV-1-positive and negative transformed T cell lines in vitro. In vivo survival studies in immunocompromised mice inoculated with human RV-ATL cells and intraperitoneally treated with C7a led to significantly increased survival of the treated mice. We investigated the mechanism of C7a activity in vitro and found that it induced mitochondrial release of cytochrome c, caspase activation, nuclear condensation and DNA degradation. These results suggest that C7a triggers apoptotic cell death in both HTLV-1 infected and uninfected human transformed T-cell lines. Significantly, C7a was not cytotoxic to peripheral blood mononuclear cells (PBMC) from healthy donors and HTLV-1-infected individuals. C7a inhibited more than 60% of the ex vivo spontaneous proliferation of PBMC from HTLV-1-infected individuals. These results support a potential therapeutic role for C7a in both ATLL and HTLV-1-negative T-cell lymphomas.
Keywords: cyclopalladated compound; HTLV-1; ATLL; chemotherapy; xenograft model; apoptosis cyclopalladated compound; HTLV-1; ATLL; chemotherapy; xenograft model; apoptosis
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Guimaraes-Correa, A.B.; Crawford, L.B.; Figueiredo, C.R.; Gimenes, K.P.; Pinto, L.A.; Grassi, M.F.R.; Feuer, G.; Travassos, L.R.; Caires, A.C.; Rodrigues, E.G.; Marriott, S.J. C7a, a Biphosphinic Cyclopalladated Compound, Efficiently Controls the Development of a Patient-Derived Xenograft Model of Adult T Cell Leukemia/Lymphoma. Viruses 2011, 3, 1041-1058.

AMA Style

Guimaraes-Correa AB, Crawford LB, Figueiredo CR, Gimenes KP, Pinto LA, Grassi MFR, Feuer G, Travassos LR, Caires AC, Rodrigues EG, Marriott SJ. C7a, a Biphosphinic Cyclopalladated Compound, Efficiently Controls the Development of a Patient-Derived Xenograft Model of Adult T Cell Leukemia/Lymphoma. Viruses. 2011; 3(7):1041-1058.

Chicago/Turabian Style

Guimaraes-Correa, Ana B.; Crawford, Lindsey B.; Figueiredo, Carlos R.; Gimenes, Karina P.; Pinto, Lorena A.; Grassi, Maria Fernanda Rios; Feuer, Gerold; Travassos, Luiz R.; Caires, Antonio C.F.; Rodrigues, Elaine G.; Marriott, Susan J. 2011. "C7a, a Biphosphinic Cyclopalladated Compound, Efficiently Controls the Development of a Patient-Derived Xenograft Model of Adult T Cell Leukemia/Lymphoma." Viruses 3, no. 7: 1041-1058.



Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert